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Summary 
Transforming growth factor fll (TGF-/30  and macrophage inflammatory protein lot (MIP-lot) 
have recently been identified as potent inhibitors of hemopoietic stem cell proliferation. From 
previous studies,  these molecules appear  to have similar  functions in the control of stem cell 
proliferation. This study was designed to investigate the relationship, if any, between these two 
negative regulators in an attempt to elucidate possible  distinctive roles  for each within the 
hemopoietic system.  We report here that both MIP-la and TGF-/3 are capable of inhibiting 
the same stem cell population (colony-forming unit [CFU]-A/CFU-S) with similar potencies. 
We further show that TGF-fl potently inhibits MIP-lot gene expression in bone marrow-derived 
macrophages, the presumed source of MIP-lt~ in the bone marrow. This inhibition is not specific 
to MIP-Iot in that expression of MIP-lfi, a related molecule that does not exhibit potent stem 
cell inhibitory properties, is inhibited in a similar manner. The inhibition of MIP-lot gene expression 
is also seen as a reduction in MIP-lc~ protein production, which markedly decreases 24 h after 
treating RAW 264.7 cells, a murine macrophage cell line, with TGF-fl. These in vitro results 
suggest that in the presence of active TGF-fi in vivo, and in the absence of upregulators of MIP- 
lot transcription, very little MIP-lot will be produced. To address how MIP-I&s target cells, 
the stem cells, would respond to TGF-fi, and the consequently low levels of MIP-lot produced, 
we analyzed the effect of TGF-fi on MIP-lc~ receptor levels on FDCP-MIX cells, a murine stem 
cell line. We show that TGF-fl (100 pM) reversibly downregulates MIP-lo~ receptor levels on 
these cells to a maximum of 50-70% after 24 h. This level of downregulation does not change 
upon increasing the concentration of TGF-~ or the length of exposure of the cells to TGF-fl. 
Scatchard analysis shows that TGF-fl downregulates MIP-lot receptor numbers with no change 
in affinity of the remaining receptors. These results suggest that TGF-~ may be capable of interfering 
with MIP-I&s role as a stem cell inhibitor. Indeed, they suggest that in the presence of active 
TGF-fl in vivo, MIP-lot is at best a weak contributor to the overall physiological  inhibition 
of stem cells. 
A  number of inhibitors of hemopoietic stem cell prolifer- 
ation have been identified recently (1), including TGF-fl 
(2), a tetrapeptide inhibitor (3), and the hemoregulatory pen- 
tapeptide (4). We have identified and characterized  another 
potent inhibitor of both murine and human hemopoietic stem 
cell proliferation, and subsequent work has revealed this mol- 
ecule to be identical to a previously identified cytokine, mac- 
rophage inflammatory protein la (MIP-loO 1 (5). We have 
also shown MIP-la to be functionally and antigenically in- 
distinguishable from an inhibitory activity present in normal 
murine bone marrow extracts. 
In vitro and in vivo results obtained thus far indicate that 
MIP-lc~ has many functional similarities  to another potent 
1Abbreviations used in  this paper: CM,  conditioned medium;  MIP-la, 
macrophage inflammatory protein lot. 
inhibitory molecule, TGF-fl. For example, it has been demon- 
strated that both of these molecules are capable of inhibiting 
primitive hemopoietic stem cell proliferation (5, 6), but ap- 
pear to be stimulatory for less primitive progenitor cells (7-9). 
Both molecules have also been shown to be active in vivo 
in inhibiting the proliferation of primitive hemopoietic cells, 
and are thus currently being investigated as potential myelo- 
protective agents for use during chemotherapy (10-12). Fur- 
thermore, TGF-fl is also functional as a potent inhibitor of 
clonogenic epidermal cells (13), and we have recently demon- 
strated MIP-la to be active in a similar manner in inhibiting 
this cellular population (14). Thus, the overlapping roles of 
TGF-/3 and MIP-lo~  are not restricted to the hemopoietic 
system and may in fact be observed in a much wider range 
of embryologically distinct cell types.  It is clear that both 
MIP-I~ and TGF-/3 are actively produced within resting bone 
marrow and skin (15-17),  and it is therefore important to 
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overall control of stem cell proliferation. 
There are no obvious structural similarities between MIP- 
loL and TGF-~ which might account for their similar func- 
tions. Indeed, whereas TGF-B is a member of a large family 
of related cytokines within which are three closely related 
mammalian TGF-~ molecules (1, 2, and 3) (18), MIP-lc~ is 
a member of a quite distinct family with very different pri- 
mary, secondary,  and tertiary structures to TGF-/$  and its 
related peptides (19, 20).  Three major receptors  for TGF-~ 
(types 1, 2, and 3) (21) have been identified in mammalian 
tissues, one of which, ~-glycan, has no signal transduction 
capacity (22),  and the other two of which (types 1 and 2) 
are believed to be involved in forming a heterodimeric com- 
plex after TGF-B binding to cells (23). The type 2 receptor 
has been cloned recently and has been shown to be a member 
of the serine/threonine kinase family of receptors  (24).  A 
human receptor for MIP-lot has recently been cloned (25, 
26) and is a member of the G-protein linked family of seven 
membrane-spanning receptor molecules (27), which also con- 
tains the receptor for the MIP-lot-related molecule, IL-8 (28, 
29).  We have shown that numerous cell types within the 
hemopoietic system have specific receptors  for MIP-lot in- 
cluding FDCP-MIX cells, a routine stem cell line, and K562 
cells, a human myeloerythroleukemic cell line (30).  Cross- 
competition analysis indicates that the receptor we are de- 
tecting on K562 cells may be identical to the recently cloned 
MIP-loJRANTES receptor, however the receptor on FDCP- 
MIX cells has a more restricted binding repertoire and may 
therefore represent a receptor specific for the stem cell inhibi- 
tory effects of MIP-lc~ and related chemokines (30).  MIP- 
loL receptors  have also been found on CTLL-R8, a T  cell 
line, and on RAW 264.7,  a macrophage cell line (31). Evi- 
dence is available implicating both Rb and c-myc (32-24) in 
the cellular response to TGF-B, although as yet, no informa- 
tion is available on the components of the MIP-lot signal 
transduction system. Such studies await the availability of a 
suitable  cell system. 
The functional redundancy coupled with the knowledge 
of their distinct molecular mature suggest that there may 
be some form of interaction between MIP-lo~  and TGF-~/ 
in the control of stem cell proliferation. It is conceivable that 
one or other of these molecules may exert its inhibitory effect 
by inducing synthesis of the other or by upregulating receptors 
or priming the necessary  signal transduction systems.  The 
aim of this study therefore was to look at any possible inter- 
actions between MIP-lot and TGF-B, and to attempt to elu- 
cidate the possible role of each in the overall control of stem 
cell proliferation. 
We now report that both MIP-lot and TGF-~ are capable 
of inhibiting the same population of hemopoietic stem cells 
(CFU-A/CFU-S cells) with similar potencies.  We further 
demonstrate that TGF-B is capable of downregulating MIP- 
lo~ gene expression  in both murine bone marrow-derived 
macrophages, the presumed source of MIP-lol in the bone 
marrow, and also in RAW cells, a murine macrophage cell 
line. TGF-fl is extremely potent in this regard. We also dem- 
onstrate TGF-B to be capable of substantially downregulating 
MIP-lo~  receptor  numbers  on  FDCP-MIX  cells  without 
affecting the affinity of the remaining receptors  for ligand. 
These in vitro results suggest therefore that in the presence 
of TGF-/~ and in the absence of positive regulators, both arms 
of the MIP-lol inhibitory response  are downregulated and 
that in vivo in the presence  of endogenous active TGF-/~, 
MIP-lc~ may be at best a weak contributor to the overall 
physiological control of hemopoietic stem cell proliferation 
in normal bone marrow. 
Materials  and Methods 
Cytokines.  Murine rMIP-lc~ was obtained from R.&D Systems, 
Inc. (Minneapolis,  MN). Human rTGF-~I was obtained  from British 
Biotechnology  Ltd. (Oxon, UK) and Gibco BRL (Paisley,  Scotland). 
The In Vitro CFU-A Assay.  Bone  marrow cells were obtained 
from female  B6D2F1 mice and prepared as suspensions by flushing 
femora with medium. For the detection of primitive progenitor 
cells, CFU-A assays  were carried out as described previously (35). 
Briefly, 2 x  104 cells in 4 ml supplemented  c~-modified  MEM con- 
taining 20% donor horse serum and 0.3%  agar were seeded on 
top of an underlayer of the same medium containing 0.6% agar, 
10% L929 cell conditioned medium ([CM] as a source of  M-CSF), 
and 10% AF1-19 T cell CM (as a source of GM-CSF) in 45-mm 
petri dishes. Cultures were incubated at 37~  in a fully humidified 
atmosphere of 10%  CO2, 5%  02, and 85%  N2 for 11 d. This 
gave rise to the formation of macroscopic colonies. Although colo- 
nies <2 mm in size do appear in the CFU-A assay, only colonies 
>2 mm in size were scored since it has been previously demon- 
strated that these larger colonies are derived from primitive hemo- 
poietic cells (36). The inhibitory cytokines  MIP-lc~ and TGF-/$ were 
tested in this assay  via direct addition to the bottom agar layer in 
various concentrations, as previously described (37). 
Derivation of  Bone Marrow  Macrophages  and Culture of RAW Cells 
and FDCP-MIX Cells.  Bone  marrow cells were obtained from fe- 
male CD1 strain  mice and prepared as suspensions  by flushing  femora 
with medium.  These cells were  suspended at  5  x  104/ml in 
c~-modified  MEM supplemented with 20% L929 CM as a source 
of M-CSF. These were incubated  at 37~  for 7 d in a dry atmosphere 
of 5% CO2 in air, and gave rise to a homogeneous population of 
bone marrow-derived macrophages as verified by immunohisto- 
chemical staining  for macrophage-specific  markers (data not shown). 
These cells were then used to investigate the effect of TGF-B on 
MIP-lce expression. 
The murine macrophage cell line RAW was maintained in spe- 
cial liquid medium (Gibco BKL)/10% FCS in a dry atmosphere 
of 5% CO2 in air. These cells were also used to investigate the 
effect of TGF-~ on MIP-lc~ expression. 
FDCP-MIX  cells were a generous gift from Professor Mike 
Dexter and Dr. Elaine Spooncer (Paterson Institute, Manchester, 
UK) and were cultured as described previously (38). Briefly, the 
cells were maintained in special liquid medium with 10% donor 
horse serum and made 10% with CM from the WEHI cell line, 
a source of IL-3. 
Gene Expression Experiments.  Bone marrow-derived macro- 
phages were starved of L929 CM and thus M-CSF for 16 h to in- 
duce growth arrest. These cells were then refed with L929 CM 
_+  250 pM TGF-/$, and total RNA was made, either 0, 1, 2, 4, 
6, or 24 h after refeeding for the time course experiment, or after 
4 h for the TGF-~ titration experiment, using a phenol-based ex- 
traction technique (ILNAzol; Cinna/Biotechx Laboratories, Inc., 
Houston, TX). 20 #g of each RNA sample was run on a 1.4% 
(wt/vol) agarose gel. The RNA was transferred  via Northern blot- 
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Herts, UK) which was baked at 80~  for 2-3 h to fix the RNA. 
A MIP-lc~ specific probe was generated as an in vitro transcription 
product of the coding sequence (279 bp) of MIP-lc~ cDNA sequence 
cloned into the pSK- Bluescript plasmid. Transcription was initi- 
ated  from the T3 promoter to give an antisense RNA  MIP-lcr 
specific probe. The probe was labeled using 32p-labeled UTP and 
separated from unincorporated nucleotides by passage through a 
Nick column (Pharmacia, Piscataway, NJ). The membrane was pre- 
hybridized at 65~  for 3 h in prehybridization buffer (50% forma- 
mide, 5x  SSPE, 5x  Denhardts, 0.1% SDS, 0.2% poly(A), 12.8% 
diethyl  pyrocarbonate  (DEPC)-treated  H20  and  0.1%  salmon 
sperm DNA of a 10 mg/ml solution). Hybridization was then per- 
formed for 16 h at 65~  in prehybridization buffer containing the 
a2p-labeled MIP-lcr  probe. The filter was then washed twice in 2 x 
SSPE/0.1%  SDS for 30 min at room temperature and then twice 
in 0.2x  SSPE/0.1% SDS for 30 min at 65~  After washing, the 
membrane(s) were exposed to Kodak x-ray film for several hours 
at  - 70~ 
For the RAW cell experiment, the same protocol as above was 
used except that the cells were starved for FCS overnight, and then 
restimulated with fresh medium and FCS. 
Western Blot Analysis.  MIP-loe protein was detected by Western 
blotting using a commercially available polyclonal antibody to MIP- 
lc~ (R&D Systems, Inc.). Briefly,  15% SDS-PAGE  gels were run 
according to the method of Laemli (39), and the gels blotted onto 
nitrocellulose filters (Schleicher & Schuell,  Inc., Keene, NH) using 
a minigel electroblotter (Atto Instruments, Inc., Rockville, MD). 
Nonspecific binding sites on the blots were blocked with a 1-h wash 
in Blotto (5% powdered milk, 0.1% NP-40 in PBS),  after which 
they were incubated, for I h, in 10 ml of a 1:1,000 dilution of the 
goat anti-MIP-lc~ antibody in Blotto. The blot was removed from 
the antibody solution and washed extensively with multiple changes 
of Blotto over a period of I  h after which it was placed in 10 ml 
of a  1:1,000  dilution  of secondary antibody (horseradish peroxi- 
dase-labeled horse anti-goat IgG; Vector Laboratories,  Inc., Burlin- 
game, CA). The blot was then finally washed extensively with mul- 
tiple changes of PBS-T (PBS/0.1% Tween 20) and the MIP-lc~ bands 
visualized using the enhanced chemiluminescence detection system 
(Amersham International,  Amersham, Buck,  UK). 
Receptor Binding Experiments.  MIP-lot was radiolabeled with 
125I as described previously (30).  Briefly,  labeling was by the io- 
dogen method and resulted in labeling to high specific activity (2.5 
x  107 cpm//zg) with full retention of biological activity. 
FDCP-MIX cells were incubated overnight at a concentration 
of 106 cells/ml with or without TGF-3 (at a concentration of 100 
pM, or as outlined in the figure legends). The cells were then washed 
twice in PBS, and 5  x  10  s cells per point aliquoted. To each ali- 
quot,  varying concentrations of nSI-labeled  MIP-lc~ were added 
in  binding  buffer  (Special  Liquid  Medium/10%  donor  horse 
serum/0.2%  azide) and either PBS or 100-fold  excess unlabeled 
MIP-lcr competitor up to a final volume of 250/zl. Cells were then 
incubated at 37~  in the above conditions for 90 min after which 
they were washed three times in PBS, and the incorporated radia- 
tion assessed in a gamma counter. Analysis  of binding isotherms 
was performed using the LIGAND program (40). 
Results and Discussion 
Direct Addition of TGF-fl and MIP-loz Can Inhibit CFU-A 
Colony Formation.  The CFU-A assay is believed to be an in 
vitro correlate of the CFU-S hemopoietic stem cell assay (35, 
36) and thus simplifies the testing of putative stem cell regula- 
tory factors.  We have previously reported  that  direct  addi- 
tion of MIP-lol to the CFU-A assay results in inhibition of 
CFU-A colony formation (37). To determine whether direct 
addition of TGF-/~ was also active on this subset of stem cells, 
we performed CFU-A assays using both of these cytokines. 
The results show that both TGF-/~ and MIP-lce are capable 
of preventing CFU-A colony formation (Fig.  1, A  and B). 
TGF-3 inhibits with an EDs0 of "~50 pM, whereas MIP-lc~ 
inhibits with an EDs0 of around  150 pM.  Previous work has 
shown  that  MIP-lol  is  also  capable  of inhibiting  CFU-A 
colony  formation  with  an  EDs0  of around  50  pM  (37). 
Thus,  it appears that both MIP-lot and TGF-3 are capable 
of inhibiting the same population of in vitro stem cells with 
similar potencies confirming the redundancy  in the actions 
of these two cytokines on this cellular population. This system 
is well characterized in terms of inhibition by MIP-lot,  and 
thus offers an ideal experimental model for studying the in- 
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Figure  1.  InhibitionofCFU-AcolonyformationbyTGF-3 
and MIP-lc~. TGF-B (A) and MIP-lot (B) were tested for in- 
hibitory activity in the direct addition CFU-A assay  (34). The 
cytokines were added directly to the feeder layers (0.6% agar 
in c~-MEM with sources of M-CSF and GM-CSF) of the 
CFU-A assays and the target cells were normal bone marrow 
cells plated at 5  x  10Vml in the upper layer (0.3% agar in 
ot-MEM). The assay  plates were incubated at 37~  in a fully 
humidified atmosphere of 10% CO2, 5% 02, and 85% N2 
for 11 d. Colonies >2 mm were scored as being CFU-A type. 
The results represent inhibition of CFU-A colony formation 
compared with control values. The above results are repre- 
sentative of more than three separate experiments. 
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tion in macrophages by TGF-/3. (A) MIP-lcx gene expression induction 
from 0 to 24 h  _+ TGF-3. Briefly, M-CSF starved bone marrow-derived 
macrophages were refed with M-CSF with or without TGF-/3 (250 pM). 
Total R.NA was made 0,  1, 2, 4, 6, and 24 h after refeeding and 20 #g 
of each RNA sample was run on a 1.4% (wt/vol) agarose gel. The RNA 
was transferred via Northern blotting, and the membrane probed using 
an MIP-lcx specific riboprobe. The autoradiograph was exposed for 18 h. 
(B) Titration of TGF-/3 downregulation of MIP-I~ gene expression. Lane 
1, 0-h control; lane 2, 4-h control; lane 3, 300 pM TGF-/3; lane 4,  100 
pM TGF-3; lane 5, 30 pM TGF-/3; lane 6, 10 pM TGF-3; lane 7, 3 pM 
TGF-/3; lane 8,  1 pM TGF-/3. Briefly, M-CSF  starved bone marrow- 
derived macrophages were refed with M-CSF plus varying  concentrations 
of TGF-3. Total RNA was made 4 h after feeding, and blotted and probed 
as described above. (C) Downregulation  of protein production by TGF-/~. 
RAW cells were starved overnight and refed with fresh medium +_  250 
pM TGF-3. CM was collected and analyzed for the presence of MIP-I~ 
protein  by Western blotting. 
teraction,  if any, between these two molecules in stem cell 
inhibition. 
TGF-I~ Can Downregulate  MIP-Ioe Gene Expression in Bone 
Marrow-derived  Macrophages.  In functioning as stem cell in- 
hibitors, it is possible that either MIP-lo~ or TGF-/3 may act 
indirectly by inducing expression of the other in nontarget 
cells, many of which are present in the CFU-A assay. To in- 
vestigate this possibility in more detail,  we have looked at 
the effects of TGF-/3  on MIP-lc~  gene expression in bone 
marrow-derived macrophages, the presumed source of MIP- 
lot in  the marrow. 
It has been shown previously that bone marrow-derived 
macrophages starved of M-CSF for 16 h enter growth arrest 
(41). Upon refeeding with M-CSF, MIP-lc~ expression is rap- 
idly induced to an optimum at around 4 h. As it is difficult 
to determine exactly what level of MIP-lc~ expression will 
be observed in normal steady state bone marrow macrophages, 
and given the low level of gene expression detected in quies- 
cent cultured macrophages,  it was decided to use this tech- 
nique of MIP-lot gene expression induction to obtain a readily 
measurable level  of expression. 
The effect of TGF-/3 on the induction of MIP-lot was in- 
vestigated as described in Materials and Methods.  Fig.  2 A 
shows a time course of MIP-lot gene expression in cells after 
refeeding with M-CSF, with or without TGF-3 as measured 
by Northern blot analysis.  As previously demonstrated,  in 
the absence of TGF-3,  MIP-lc~ is induced to an optimum 
at around 4 h after feeding, with this level beginning to de- 
cline to resting levels within 24 h. In the presence of TGFq3 
however, the induction of MIP-lol expression is essentially 
inhibited throughout the time course investigated. Even after 
24 h, densitometric analysis shows that expression of MIP-lot 
in TGF-/3 treated cells remains inhibited by 87% compared 
with the control cells. Reprobing of blots for glyceraldehyde 
3-phosphate dehydrogenase  (GAPDH) mRNA revealed similar 
loadings in all tracks (data not shown).  It appears therefore 
that TGF-/3 is capable of inhibiting the induction of MIP-lot 
gene expression in bone marrow-derived macrophages,  the 
presumed source of MIP-lot in the bone marrow, and whereas 
for practical reasons we have observed this effect during in- 
duction of MIP-lot gene expression,  it is evident from the 
varying levels of MIP-lot induction seen in Fig. 2 A that such 
an effect is observed at a range of levels of MIP-I~ gene ex- 
pression, even as low as those detected in normal bone marrow. 
To assess the potency of this effect, we performed a titra- 
tion of the effects of TGF-/3 on MIP-lot gene expression using 
the methodology outlined above. Cells were studied at 4 h 
after feeding as this leads to the optimum induction of MIP- 
lol  gene  expression,  therefore  allowing  any inhibition  by 
TGF-/3 to be easily measured. The results show MIP-lot gene 
expression to be inhibited in a dose-dependent manner (Fig. 
2 B), and even at concentrations of TGF-3 as low as 1 pM, 
densitometric  analysis  shows that  MIP-lc~ gene expression 
is reduced by ,,o70% compared with control values.  TGF-B 
is therefore very potent  in  the inhibition  of MIP-lot  gene 
expression, and appears to be capable of mediating this effect 
at  femtomolar  concentrations. 
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TGF-B. A time course of MIP-1B gene expression induction from 0 to 
24 h  _+  TGF43. Briefly, the membrane shown in Fig. 2 was stripped of 
MIP-la specific probe by boiling in several hundred milliliters of 0.05 x 
SSC, 0.01 M EDTA (pH, 8.0), and 0.1% SDS for 10 min. The filter was 
then rinsed in 0.01 x  SSC at room temperature and probed with a MIP-1B 
specific riboprobe.  The autoradiograph  was exposed for  18 h. 
TGF-/3 Downregulates MIP-Iot Protein Synthesis.  We have 
demonstrated similar inhibition of MIP-lc~ gene expression 
in RAW cells (data not shown), the murine macrophage cell 
line from which MIP-lol was initially isolated (19). This cell 
line produces detectable levels of MIP-lol protein and thus 
has allowed us to investigate the effects of  the observed TGF-B 
downregulation of MIP-lol gene expression on MIP-la pro- 
tein levels. Such analysis is difficult in cultured macrophages 
because of  the very low and often undetectable levels of  MIP- 
lol protein production (data not shown). 
Results  from an analysis of CM from control and TGF- 
B-treated RAW cells for presence of MIP-lo~ protein using 
Western blotting (Fig. 2 C) indicate that in the presence of 
TGF-B, MIP-la protein levels are substantially reduced, and 
that this effect is evident even after only 24 h. This inhibi- 
tion was maintained over the 96-h time course of this ex- 
periment. 
These results suggest  that the inhibition of gene expres- 
sion by TGF-B is also observed as an inhibition of protein 
synthesis and that the potent blocking of MIP-la produc- 
tion by TGF-B may have important physiological and func- 
tional implications. 
TGF-/3 Downregulates MIP-1/~ Gene Expression in  Bone 
Marrow-derived Macrophages.  To  investigate  whether  the 
TGF-B inhibition of  MIP-la expression was a specific  effect, 
we have examined the effect of TGF-B on MIP-1B gene ex- 
pression in bone marrow-derived macrophages. MIP-1B is 
a related molecule to MIP-lol, but, with the exception of 
recombinant material produced in prokaryotic systems, it does 
not appear to exhibit stem cell inhibitory properties (30). A 
time course was performed as outlined in the previous ex- 
periments and the blot probed with a MIP-1B specific  probe. 
The results (Fig. 3) show that TGF-B can also inhibit MIP- 
1B gene expression, and therefore it appears that TGF-B is 
not specific in inhibiting MIP-lot gene expression in bone 
marrow-derived macrophages. 
Much evidence  is now available  pointing to a role for TGF-B 
as a modulator of  inflammatory cytokine production (42, 43), 
and it has been shown previously that TGF-/3 is a potent deac- 
tivator of macrophages (44). It is likely that the downregula- 
tion of MIP-lol and MIP-1B cytokine production falls into 
this category of cellular control and may not be specifically 
related to stem cell inhibition.  It is interesting to note in this 
context that we have also demonstrated TGF-B to be active 
in inhibiting induction of MIP-lo~ after treatment of bone 
marrow-derived macrophages with LPS (data not shown). 
The more general nature of the TGF-B downregulation of 
MIP-la is, however, to a large extent irrelevant as the demon- 
stration  of the ability of TGF-B to downregulate MIP-lol 
protein synthesis suggests that it will interfere with all of 
the MIP-lc~-mediated functions, and not simply those relating 
to immunological phenomena. 
Recently, targeted disruption studies on the TGF-B1 gene 
have been reported (45), and analysis of the cytokine profile 
of these animals indicate MIP-lc~ gene expression to be up- 
regulated in the TGF-Bl-deficient mice compared with con- 
trol mice. This is interpreted as being a secondary product 
of the tissue inflammation observed in the TGF-Bl-deficient 
mice. The present results indicate that this may, at least in 
the case of MIP-lo~, be a more specific result of removal of 
a TGF-B block on cytokine gene expression. Such a conclu- 
sion would predict that TGF-B2 and TGF-B3 would not be 
potent downregulators of MIP-lcr gene expression, as these 
genes are intact in the transgenic mice. We are currently in- 
vestigating the effects of these isoforms of TGF-B in this 
regard. 
TGF./3 Can Downregulate  MIP-Iot Receptors on FDCP-MIX 
Cells.  Given  the observed  response of  macrophages (the likely 
in vivo source of MIP-lo  0  to TGF-B,  we have also inves- 
tigated what, if any, response is observed in the MIP-lol target 
cells. To address this  question,  we have studied  the effects 
of  TGF-B on the levels of  receptor for MIP-la on hemopoietic 
stem cell like lines. The specific cell line used in the current 
study was the murine FDCP-MIX cell line which, as ini- 
tially isolated, displays considerable similarity to the CFU-S 
stem cell (38). We have previously demonstrated these cells 
to have  numerous cell surface receptors for MIP-lo~ and have 
also shown these receptors to be specific in recognizing only 
those members of  the MIP-lo~ peptide family that are capable 
of stem cell inhibition (30). Receptor binding assays were 
performed as described in Materials and Methods.  Initially, 
binding was performed using a titration of radiolabeled MIP- 
lc~ to investigate the effects of TGF-B on MIP-lc~ receptor 
levels. MIP-lo~ receptor levels are typically saturated at around 
I nM, however, when cells are incubated with TGF-B, the 
MIP-la receptor levels on the cell surface appear to be re- 
duced by '~50% (Fig. 4). We have shown that TGF-B does 
not compete with MIP-lc~ for binding to its receptor and 
thus these results do not simply reflect TGFq3 blocking of 
MIP-lol receptor binding. More comprehensive  binding curves 
were carried out (Fig. 5) and Scatchard analysis of the data 
performed to investigate whether the observed downregula- 
tion results from reduction in receptor numbers or receptor 
affinity. The results indicate that whereas the control cells 
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Figure  6.  Titration of TGF-/~-mediated  downregulation of MIP-Io~ 
receptors. FDCP-MIX cells treated for 24 h with varying concentrations 
of TGF-~ were treated as outlined in Fig. 4 and specific binding of 12Sl- 
labeled MIP-loe measured. The results are expressed as percent incorpora- 
tion of 125I MIP-lc~ compared  with control cells. 
Figure  4.  TGF-fl downregulates MIP-lol receptors on FDCP-MIX cells. 
Titration of specific binding of 12SI-labeled MIP-la to FDCP-MIX cells 
after treatment with or without TGF-fl (100 pM). FDCP-MIX cells were 
incubated  overnight at a concentration  of 106 cells/ml  _+  TGF-fl after 
which the cells were washed  twice in PBS and 5  x  10  s cells per point 
aliquoted.  To each aliquot, varying concentrations  of lzSI-labeled MIP- 
la were added in binding buffer and either PBS or 100-fold excess unla- 
beled MIP-lc* competitor.  Cells were then incubated at 37~  for 90 rain 
after which they were washed 3 times in PBS and the incorporated  radia- 
tion assessed in a gamma counter. Data are representative of three experi- 
ments and are plotted as the mean of duplicate  determinations. 
expressed •11,000  receptors per cell, the TGF-3-treated cells 
expressed only 3,400 receptors per cell, indicating a 70% reduc- 
tion in receptor numbers. MIP-lo~ receptors on control cells 
exhibited a Ka of 1.3  x  10 -9 compared with  1.21  x  10 -9 
for the TGF-/~-treated cells. Thus, TGF-~ inhibition of MIP- 
lc~ receptors is due to a decrease in receptor number and not 
to  a  decrease in  receptor  affinity.  The  Kd of the  MIP-lc~ 
CPM  / 
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Figure  5.  Analysis  of TGF-3-mediated downregulation  of MIP-I~ 
receptor levels. Equilibrium binding of lz~I-labeled  MIP-la to FDCP-MIX 
cells. Cells were preincubated  in medium with or without TGF-3 (100 
pM) for 18 h and binding of mSI-labeled MIP-lo~ assessed as outlined in 
Fig.  4. 
receptors measured in the present study is approximately three 
times  that  measured  in previous studies  (30).  The  reasons 
for this are unclear but may reflect variations in the molec- 
ular weight of the MIP-lc~ used in the binding studies (for 
a discussion  see reference 30). 
To fully characterize  the kinetics of this receptor down- 
regulation,  and to ascertain the maximum  downregulation 
that could be obtained, a titration from 50 pM to 1 nM TGF-~/ 
was performed. Fig. 6 shows that after 24 h, the maximum 
downregulation  appears  to be ,,o50%,  and this is achieved 
using TGF-~/at a concentration of 100 pM. The maximum 
downregulation achievable varied from experiment to experi- 
ment from between 50 and 70%. Increasing the concentra- 
tion of TGF-3 does not however cause a further decrease in 
MIP-lol  receptor  numbers. 
In vivo, it is possible that  stem cells are continually  ex- 
posed to active TGF-B and preliminary evidence from studies 
on long-term exposure of FDCP-MIX cells to TGF-B indi- 
cate that such continued exposure maintains the reduced levels 
of MIP-lc~ receptors on FDCP-MIX cells.  If a single treat- 
ment of TGF-B is applied to the cells,  the MIP-lc~ receptor 
levels  are  seen  to  return  to  normal  within  72 h  (data  not 
shown). This suggests that the TGF-3-mediated inhibition 
of MIP-lc~  receptor  levels  is  fully reversible  but  that  on 
prolonged exposure, such as may be encountered in vivo, MIP- 
lc~ receptor levels will be downregulated on cells for the du- 
ration  of their  exposure to  TGF-B. 
Demonstration  of receptor downregulation by TGF-3 is 
not peculiar to MIP-Ioe receptors and has been observed for 
a range of receptor molecules, most notably those for IL-3, 
G-CSF, and GM-CSF (46).  Indeed, it is postulated that one 
of the modes of inhibitory action of TGF-~/on hemopoietic 
stem cells involves downregulation of receptors for mitogenic 
stimuli,  thus blocking response to these factors.  In contrast 
to the three factors mentioned above, the MIP-lo~ receptor 
is likely not  to be a member  of the  hemopoietin  receptor 
family, and thus the ability of TGF-3 to downregulate cytokine 
receptor levels may be a very general phenomenon affecting 
receptors for both mitogenic and inhibitory cytokines. Again, 
although these results have been obtained using in vitro cel- 
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regulate MIP-lot receptor levels on any cells, including stem 
cells, that are exposed to active TGF-/3. The functional sig- 
nificance of a 50-70% reduction in MIP-lot levels on FDC- 
MIX ceils in terms of ability to respond to MIP-lot is un- 
clear. Certainly it is apparent from studies with other receptor/ 
ligand systems that only partial receptor occupancy is often 
sufficient for generation of full biological effect (47), and it 
remains a formal possibility that the remaining 30--50% of 
MIP-lot receptor may be sufficient to achieve this end. This 
possibility is currently under  investigation. 
Conclusions.  The results presented in this manuscript show 
TGF-~8 to be a potent downregulator of MIP-lot production 
by bone marrow macrophages and also of MIP-lc~ receptor 
levels on primitive hemopoietic cells in vitro.  These results 
suggest that in vivo, in the presence of active TGF-B which 
has been demonstrated to be present in normal bone marrow 
and in the absence of additional  factors which may act  to 
upregulate MIP-lot, MIP-lcr  may only be a weak contrib- 
utor to inhibition  of hemopoietic stem cells.  It may be that 
MIP-lot is relatively more important in inhibiting stem cells 
during  or after stress,  or in  situations  in which  TGF-~  is 
present  in low levels. 
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